Sumitomo Dainippon   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Osaka China (1995)

Organization Overview

First Clinical Trial
2004
NCT00101426
First Marketed Drug
2010
alcaftadine (Lastacaft)
First NDA Approval
2010
alcaftadine (Lastacaft)
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Dainippon Sumitomo | Dainippon Sumitomo Pharma America | Dainippon Sumitomo Pharma Co., Ltd. | Dainippon Sumitomo Pharma Europe LTd. | Sumitomo Dainippon Pharma | Sumitomo Dainippon Pharma Co., Ltd. | Sumitomo Dainippon Pharma Oncology | Sumitomo Dainippon Pharma Oncology, Inc | Sumitomo Dainippoon Pharma | Valent Technologies, Inc.